NanoViricides Targets Congo Ebola Emergency With High-Efficacy Antiviral

Shelton, Tuesday, 26 May 2026.
NanoViricides is deploying its experimental antiviral, NV-387, to the DRC. Targeting the untreatable Bundibugyo Ebola strain, the drug’s remarkable 170% survival increase in prior trials presents significant market implications.